In conclusion, QHF can significantly alleviate hepatic steatosis and inflammation in NASH mice by upregulating SOCS1 to inhibit the TLR4/NF-κB signaling pathway. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatohepatitis.